...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Leukemia and lymphoma >Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)
【24h】

Role of plerixafor in autologous stem cell mobilization with vinorelbine chemotherapy and granulocyte-colony stimulating factor in patients with myeloma: a phase II study (PAV-trial)

机译：培瑞沙福在长春瑞滨化疗和粒细胞集落刺激因子对骨髓瘤患者的自体干细胞动员中的作用：II期研究（PAV试验）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Current practice in Switzerland for the mobilization of autologous stem cells in patients with myeloma is combining vinorelbine chemotherapy and granulocyte-colony stimulating factor (G-CSF) cytokine stimulation. We prospectively investigated adding intravenous plerixafor to the vinorelbine/G-CSF combination (VGP), and compared it with vinorelbine/plerixafor (VP) and G-CSF/plerixafor (GP) combinations. In a final cohort (VP-late), plerixafor was given on the first day of CD34 + cells increasing to > 15 000/mL peripheral blood. Four consecutive cohorts of 10 patients with myeloma were studied. We observed that intravenously administered plerixafor can be safely combined with vinorelbine/G-CSF. VGP was superior in mobilizing peripheral stem and progenitor cells compared to the three double combinations (VP, GP and VP-late), and GP mobilized better than VP. Our data indicate that the triple combination of VGP is an efficient strategy to collect autologous CD34 + cells, with G-CSF contributing predominantly in this concept. Plerixafor can be safely added to G-CSF and/or vinorelbine chemotherapy.
机译：瑞士目前在骨髓瘤患者中动员自体干细胞的实践是将长春瑞滨化疗与粒细胞集落刺激因子（G-CSF）细胞因子刺激相结合。我们前瞻性地研究了在长春瑞滨/ G-CSF组合（VGP）中添加静脉注射的培雷沙福，并将其与长春瑞滨/培立沙福（VP）和G-CSF /培瑞沙福（GP）组合进行比较。在最后一个队列（VP-后期）中，在CD34 +细胞的第一天给予了plerixafor，其外周血浓度增加至> 15000 / mL。研究了10名骨髓瘤患者的四个连续队列。我们观察到静脉内施用的plerixafor可以与长春瑞滨/ G-CSF安全合并使用。与三个双重组合（VP，GP和VP-late）相比，VGP在动员周围干细胞和祖细胞方面更胜一筹，而GP在动员方面比VP更好。我们的数据表明，VGP的三重组合是收集自体CD34 +细胞的有效策略，其中G-CSF在此概念中起主要作用。可以将Plerixafor安全地添加到G-CSF和/或长春瑞滨化疗中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号